Theravance Biopharma, Inc. (TBPH)

Market Cap	401.65M
Revenue (ttm)	62.02M
Net Income (ttm)	-45.65M
Shares Out	48.92M
EPS (ttm)	-0.92
PE Ratio	n/a
Forward PE	18.21
Dividend	n/a
Ex-Dividend Date	n/a

Volume	111,782
Open	8.24
Previous Close	8.28
Day's Range	8.21 - 8.31
52-Week Range	7.44 - 11.71
Beta	0.25
Analysts	Buy
Price Target	13.75 (+67.48%)
Earnings Date	Nov 12, 2024

About TBPH

Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States and Europe. It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). The company’s product includes Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; and TRELEGY for the treatment of COPD and asthma. It has licensing and collabora...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2013
• Employees: 99
• Stock Exchange: NASDAQ
• Ticker Symbol: TBPH
• Website: https://www.theravance.com

Analyst Forecast

According to 4 analysts, the average rating for TBPH stock is "Buy." The 12-month stock price forecast is $13.75, which is an increase of 67.48% from the latest price.

Price Target

$13.75

(67.48% upside)

Analyst Consensus: Buy